Failed oral immunotherapy should be considered as a risk factor for fatal anaphylaxis, and omalizumab treatment considered
Abstract Oral immunotherapy is proposed as the only active intervention to modify allergies and decrease the risk of severe reactions. However, it is crucial to note that oral immunotherapy still presents a notable failure rate and potential for severe, life-threatening outcomes. Notably, patients w...
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMC
2024-11-01
|
| Collection: | Italian Journal of Pediatrics |
| Sujets: | |
| Accès en ligne: | https://doi.org/10.1186/s13052-024-01814-7 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|